Table 1.
Comparison of multiplier and benchmark datasets as well as external data.
| Description | ||||||
|---|---|---|---|---|---|---|
| SMSR | SMSR | SVK | SVK augmented | Mediservice | SMSC | |
| All with CDMS | DMT in last 12 months | DMT in 2016 | DMT in 2016 | DMT in 2016 | In care at MS centers | |
| N | 1,567 | 973 | 6,057 | 9,503 | 4,613 | 1,115 |
| Female | 73.6% | 78.0% | 71.3% | 71.2% | 71.0% | 65.8% |
| Median age (IQR) | 48 (38–56) | 44 (36–52) | 45 (36–53) | 45 (36–53) | – | 41 (33–50) |
| Age Categories | ||||||
| 19–49 | 55.5% | 68.2% | 63.6% | 65.6% | 63.7% | – |
| 50–64 | 34.5% | 28.4% | 30.5% | 28.7% | 30.2% | – |
| 65 and older | 10.1% | 3.4% | 5.9% | 5.7% | 6.1% | – |
| DMT status | ||||||
| % never received DMT | 13.8% | – | – | – | – | 7.2% |
| % ever exposed to DMT | 24.1% | – | – | – | – | 12.6% |
| % receiving DMT in last 12 mt | 62.1% | 100% | 100% | 100% | 100% | 80.2% |
| DMT type | * | |||||
| No treatment | 37.9% | – | – | – | – | 19.8% |
| Interferon/Glatiramer Acetate | 15.2% | 24.5% | 31.4% | 33.9% | 38.8% | 7.9% |
| Oral | 37.1% | 59.8% | 56.8% | 53.0% | 57.1% | 49.7% |
| Other infusion therapies | 9.8% | 15.7% | 11.9% | 13.0% | 4.1% | 21.1% |
| MS type | ** | |||||
| Relapsing-remitting MS | 72.2% | 90.8% | 94.4% | 94.8% | – | 86.3% |
| Secondary-progressive MS | 16.8% | 9.2% | 5.6% | 5.2% | – | 5.3% |
| Primary-progressive MS | 10.9% | – | – | – | – | 4% |
| Disease duration from FS (IQR) | 11 (6–19) | 9 (5–16) | 8.0 (3.6–14.2) | 8.1 (3.8–14.2) | – | 10.0 (5.5–16.7) |
| Region | ||||||
| Lake Geneva region | 11.5% | 11.2% | 8.3% | 14.1% | 7.7% | – |
| Midlands | 25.1% | 24.9% | 22.6% | 24.6% | 24.4% | – |
| North-western Switzerland | 16.6% | 16.0% | 18.9% | 16.5% | 19.1% | – |
| Eastern Switzerland | 14.1% | 14.3% | 17.1% | 13.8% | 17.7% | – |
| Ticino | 3.5% | 3.5% | 0.9% | 3.0% | 5.5% | – |
| Central Switzerland | 8.3% | 8.4% | 11.8% | 9.5% | 10% | – |
| Zurich | 20.9% | 21.7% | 20.4% | 18.5% | 15.7% | – |
Columns 1 and 2 display the population characteristics of the Swiss Multiple Sclerosis Registry in total (column 1) and the subsample which used DMT in the last 12 months (column 2). Columns 3 and 4 display the information of the Swiss national MS treatment registry dataset as well as the augmented Swiss nation MS treatment registry dataset which represents the entire population of persons with MS using a DMT in 2016. Column 4 displays the characteristics of the Mediservice dataset, which is an aggregated dataset that contains information about persons with MS using the drug delivery and handling service of the MediService company. Column 5 shows aggregated data of the Swiss Multiple Sclerosis Cohort (SMSC) study, a clinic based, longitudinal cohort in Switzerland in 2016.
1.5% have other DMTs.
4.1% have a CIS. CDMS, Clinically Definite Multiple Sclerosis; DMT, Disease-Modifying therapies; FS, First Symptoms; IQR, Interquartile Range; MS, Multiple Sclerosis; SMSC, Swiss Multiple Sclerosis Cohort; SMSR, Swiss Multiple Sclerosis Registry; SVK, Swiss national MS treatment registry.